搜尋結果
Eisai Co., Ltd.｜A human health care company. News Release. Latest News. Information. August 6, 2024. Update Regarding the Regulatory Status of LEQEMBI® Subcutaneous Formulation. August 1, 2024. REVENUE OF LEQEMBI® (PRELIMINARY BASIS) August 1, 2024. Eisai Announces Status Relating to Acquisition of Own Shares.
AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen.
Welcome to the Eisai Official Corporate Website About Eisai Page. This website uses cookies to enhance your browsing experience. By using this site, you agree to our use of cookies. If you do not wish to accept cookies in connection with your use of this ...
Welcome to the Eisai Official Corporate Website Eisai Group Worldwide Page
Eisai at a Glance. A Leading Global Research and Development-Based Pharmaceutical Company Headquartered in Japan. Established in 1941, Eisai is a pharmaceutical company operating globally in terms of R&D, manufacturing and marketing, with a strong focus on prescription medicines.
INDICATION. LEQEMBI® [(lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) reconfirmed today that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (generic name: lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows.
